Which insiders are buying Valeant Pharmaceuticals International, Inc. (VRX)?

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) marched up 113.89% compared to a 52-week low price of $10.94. The shares were last seen trading -3.43% lower, taking the closing price at $23.4 on 07/13/2018. At recent session, the prices were hovering between $23.36 and $24.43. This company shares are -3.25% up from its target price of $22.64 and the current market capitalization stands at $8.28B. The recent change has given its price a 2.64% lead over SMA 50 and -15.8% deficit over its 52-week high. The stock witnessed -12.88% declines, 36.44% gains and -1.72% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VRX’s volatility during a week at 3.44% and during a month it has been found around 3.65%.

Valeant Pharmaceuticals International, Inc. (VRX) Top Holders

Institutional investors currently hold around $3.87 billion or 66.8% in VRX stock. Look at its top three institutional owners. Paulson & Co. Inc. owns $487.63 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.89% of the company’s market cap and approximately 12.6% of the institutional ownership. Similar statistics are true for the second largest owner, Valueact Holdings, L.P., which owns 18,011,537 shares of the stock are valued at $421.47 million. The third largest holder is Connor, Clark & Lunn Investment Management Ltd., which currently holds $208.45 million worth of this stock and that ownership represents nearly 2.52% of its market capitalization.

Valeant Pharmaceuticals International, Inc. 13F Filings

At the end of March reporting period, 145 institutional holders increased their position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) by some 29,734,492 shares, 158 decreased positions by 39,349,490 and 69 held positions by 96,344,566. That puts total institutional holdings at 165,428,548 shares, according to SEC filings. The stock grabbed 54 new institutional investments totaling 12,581,807 shares while 44 institutional investors sold out their entire positions totaling 8,442,035 shares.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Insider Trades

Multiple company employees have indulged in significant insider trading. Valeant Pharmaceuticals International, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director De Schutter Richard U has acquired 10,000 shares of Valeant Pharmaceuticals International, Inc. (VRX) in trading session dated May. 15, 2018. These shares are worth $218,000 and were traded at $21.8 each. The SEC filing shows that De Schutter Richard U performed a purchase of 15,000 shares. The Director added these shares by way of transaction on May. 15, 2018. The company’s shares were assimilated at $21.83 per share worth to an investment of some $327,450 on account of De Schutter Richard U.

CHAIRMAN & CEO, Papa Joseph C, purchased 30,000 common shares of Valeant Pharmaceuticals International, Inc. (VRX) in the open market. In a transaction dated Mar. 13, 2018, the shares were bought at an average price of $16.05, giving away a sum of $481,500. After this purchase, 719,019 common shares of VRX are directly owned by the insider, with total stake valued at $16,825,045.

In the transaction dated Mar. 13, 2018, the great number of shares acquired came courtesy the EVP and CFO; Herendeen Paul added a total of 15,000 shares at an average price of $16.1, amounting to approximately $241,500. The insider now directly owns 231,492 shares worth $5,416,913.

Valeant Pharmaceuticals International, Inc. (VRX) Analyst Guide

Several analysts have released their opinion on Valeant Pharmaceuticals International, Inc. (NYSE:VRX), with 6 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 3 strong sell ratings, collectively assigning a 2.54 average brokerage recommendation.